Abstract
In this educational post, I walk you through how the sex hormone triad—testosterone, estradiol (estrogen), and progesterone—shapes mood, cognition, sleep, pain, metabolism, and sexual function in women and men. Drawing on the latest findings from leading researchers and my integrative chiropractic practice in El Paso, I explain hallmark symptom patterns (such as 2:00–4:00 a.m. awakenings, afternoon energy crashes, hot flashes, and loss of drive), clarify the physiology behind these patterns, and compare evidence-based treatment strategies including pellets, transdermals, patches, injections, and rapid-dissolve tablets. I detail nuanced decision-making for different ages and sexes, highlight monitoring and safety, and show how integrative chiropractic care—with autonomic balancing, spinal-neuroimmune modulation, restorative movement, and nutrition—amplifies outcomes. Throughout, I include dosing pearls, clinical flow, special situations (perimenopause, low libido, menstrual migraine, breast cancer survivorship). You will see how modern, evidence-based research methods inform a layered, patient-centered approach that restores physiologic rhythms and resilience.
Understanding Hormone Signals: Why Mood, Sleep, and Drive Shift
In my daily practice, patients often describe feeling anxious, irritable, wired yet exhausted, unfocused, and flat. They tell me "I wake at 2 or 3 AM wide awake," "I hit a wall around 2 PM," or "my get-up-and-go got up and left." These are not random complaints; they reflect neuro-hormonal mismatch—an imbalance between the brain's arousal systems and endocrine signals that normally buffer stress and stabilize sleep and motivation.
Key Patterns I See Clinically
Early morning 2:00–4:00 a.m. wake-ups: a hallmark of sympathetic overdrive and HPA axis dysregulation
Afternoon energy crash (1–4 p.m.): temporarily relieved by caffeine, often signaling adrenal strain and low sex-steroid support
Loss of drive and enjoyment: diminished dopamine-reward tone often linked to low testosterone
Low libido or reduced morning erections in men: sensitive biomarker for declining nocturnal androgen signaling
Night sweats and hot flashes: estradiol deficiency and hypothalamic thermoregulatory shifts
Chronic pain and fibromyalgia-like symptoms: frequently intersect with low sex steroids and sleep fragmentation
Why These Patterns Emerge: The Physiology
HPA axis dysregulation: Chronic stress elevates CRH and ACTH, raising nocturnal cortisol when it should be falling. This fragments sleep and elevates sympathetic tone (Lightman, Birnie, & Conway-Campbell, 2020).
Sex steroids as neurosteroids: Estradiol, progesterone, and testosterone modulate GABA and glutamate, synaptic plasticity, and neuroinflammation. Low levels tilt the brain toward hypervigilance and poor sleep consolidation (Barth, Villringer, & Sacher, 2015; Schumacher et al., 2014).
Testosterone and reward: Low testosterone blunts mesolimbic dopamine, reducing motivation, hedonic tone, and libido; in men, it aligns with loss of morning erections (Corona et al., 2014).
Estrogen and thermoregulation: Estradiol influences KNDy neurons and hypothalamic setpoints; deficiency expands the thermoneutral zone and triggers vasomotor symptoms (Rance, Young, & Morrison, 2013; Santoro, Epperson, & Mathews, 2021).
Progesterone and GABA-A modulation: Micronized progesterone and its metabolite allopregnanolone are positive GABA-A modulators that calm anxiety and enhance sleep; deficits heighten irritability and insomnia (Schüssler et al., 2018).
Clinical pearl: When patients report clustered mood, sleep, and libido changes—especially 2–4 a.m. awakenings and afternoon crashes—I evaluate estradiol, progesterone (women), total and free testosterone, SHBG, LH/FSH, DHEA-S, TSH/free T4, vitamin D, ferritin, and morning cortisol. I always pair labs with symptom timing; timing tells the story.
Male Androgen Insufficiency: Why Morning Erections Matter
Men often say, "Hobbies feel flat," or "my morning erections are gone." That matters clinically.
Morning erections reflect intact parasympathetic vascular tone and sufficient nocturnal androgen signaling. Decline often precedes daytime symptom recognition and aligns with falling free testosterone or rising SHBG.
Metabolic drag, including central adiposity and insulin resistance, may accompany androgen insufficiency, exacerbating fatigue and mood flattening (Grossmann, 2018).
In care plans, I aim to restore steady androgen tone without exaggerated peaks that spike aromatization into estradiol and destabilize mood.
Women's Hormone Transitions: Perimenopause Through Postmenopause
In women, the earliest signals are mood and sleep lability. In the forties, progesterone generally declines earlier and more sharply than estradiol. This imbalance drives:
Anxiety, insomnia, irritability: insufficient GABAergic modulation
Heavy or irregular bleeding and breast tenderness: relative estrogen dominance
Night sweats and hot flashes: later-stage estradiol decline and hypothalamic thermoregulation shifts
Principles I Apply
Perimenopause: Prioritize calming the nervous system and stabilizing cycles. Nightly micronized progesterone can be transformative for sleep and mood.
Early postmenopause: Estradiol support improves vasomotor symptoms, sleep, and bone turnover.
Late postmenopause: "Start low, go slow"—long-term deprivation downregulates receptor populations; conservative titration avoids adverse effects.
I also track FSH dynamics to stage menopause and follow response trends. FSH rises as estradiol falls; after therapy initiation, a gradual reduction in FSH (often by half in early cycles) correlates with symptom improvement over months (Burger, 2011).
Evidence-Based Treatment Routes: Pros, Cons, and Clinical Fit
I select modalities based on physiology, lifestyle, sensitivity, and safety—and I layer changes to isolate cause and effect.
Bioidentical Pellets
What: Compounded estradiol and testosterone pellets placed subcutaneously for continuous release over 3–5 months.
Why patients like them: Steady-state delivery avoids peaks/troughs common with injections or daily gels, resulting in smoother mood and energy (Davis & Wahlin-Jacobsen, 2015).
Considerations:
Not easily removable; the dose must run its course.
Kinetics vary by body fat, blood flow, and pellet manufacturing specifics.
Side effects can persist longer due to continuous exposure.
When I use pellets:
Patients valuing convenience and struggling with volatility on other routes
Women with severe vasomotor/sleep symptoms not controlled by patches or gels
Men who prefer stable delivery with consistent monitoring
Transdermal Creams and Gels
Pros: Non-invasive, flexible dosing, bypasses the hepatic first-pass.
Absorption nuances: Skin thickness, site, temperature, and vehicle matter; scrotal or labial application yields superior absorption in men and women, respectively (Handelsman, 2020).
Pearls:
Alcohol-based gels can irritate thin genital skin; use intact skin (neck/shoulders).
Avoid transfer to partners/children (Bhasin et al., 2018).
Vaginal estradiol is excellent for genitourinary syndrome of menopause (GSM) but rarely yields systemic levels sufficient for vasomotor control (The North American Menopause Society, 2022).
Transdermal Patches
Why I favor patches for many women:
Consistent estradiol delivery and favorable VTE/stroke risk versus oral estrogens (Vinogradova, Coupland, & Hippisley-Cox, 2019).
Broad insurance coverage and practical dose ranges.
Tip: Higher BMI or dermal characteristics may require mid-range doses to achieve target serum levels.
Injections
Use in men: Intramuscular or subcutaneous testosterone cypionate is common. I avoid high intermittent peaks.
Starting points I use:
Men: 100–200 mg weekly or 50–60 mg twice weekly, adjusted to symptoms and labs (Bhasin et al., 2018).
Women: microdoses (5–12 mg/week subcutaneous) to minimize virilization; split dosing reduces peak levels.
Clinical caveats:
High peaks intensify aromatization to estradiol, causing mood lability or breast tenderness.
In women, infrequent IM dosing raises the risk of acne, alopecia, voice change, and clitoromegaly.
Subcutaneous lumps respond to smaller, more frequent doses and local massage.
Oral, Sublingual, and Rapid-Dissolve Tablets
Estradiol:
Oral estradiol is effective but increases hepatic production of clotting factors; consider transdermal administration to lower VTE risk (Vinogradova et al., 2019).
Sublingual/rapid-dissolve estradiol bypasses the first pass and yields predictable peaks when sampled 3–4 hours post-dose.
Vaginal estradiol is best for GSM; not adequate alone for systemic symptoms.
Progesterone:
Micronized oral progesterone (200 mg nightly) is standard for endometrial protection in postmenopausal women on systemic estrogen (The North American Menopause Society, 2022).
In perimenopause, 100–200 mg at night eases sleep and anxiety; nightly or luteal-phase targeting based on symptoms.
Avoid progesterone creams for endometrial protection; they are not adequate.
Testosterone tablets:
Oral testosterone undecanoate exists for men; modern formulations mitigate hepatic impact but require monitoring (Saad, Yassin, & Doros, 2021).
In women, low-dose rapid-dissolve testosterone (2–10 mg) can improve libido and vitality with fewer side effects compared to injections.
Layered Therapy: Why "Start Low, Go Slow" Works
I rarely introduce multiple hormones at full dose simultaneously—especially in women who are more sensitive to neuroendocrine shifts. Layering isolates cause and effect, respects receptor adaptation and binding protein (SHBG) dynamics, and reduces adverse events.
Receptor kinetics: Sex hormone receptors modulate gene transcription over days to weeks; abrupt multi-hormone changes overshoot physiologic set points, causing headaches, mood swings, breast tenderness, or acne.
SHBG buffering: SHBG modulates the availability of free hormones. Changing several hormones can unpredictably shift free fractions, particularly in women with high or low SHBG.
Neurosteroid effects: Progesterone's GABAergic impact can soothe or sedate; dosing too quickly can destabilize sensitive responders.
When switching modalities (e.g., injections to gel, gels to pellets), I often overlap for a short window to prevent troughs while the new route equilibrates. This keeps symptoms stable and avoids unnecessary dose escalation.
Validated Symptom Tools and Labs: Anchoring Care in Data
I believe in measuring what matters. To anchor care in the patient’s voice and in objective trends, I use validated tools and comprehensive labs.
Symptom Inventories
Menopause Rating Scale (MRS) and AIMS: Baseline and follow-up assessments quantify changes in vasomotor, sleep, cognitive, pain, and sexual function, guiding shared decision-making (Heinemann, Potthoff, & Schneider, 2004).
Laboratory Strategy
Core panel: Total and free testosterone (direct assay), LH/FSH, TSH/free T4/free T3, CBC, CMP.
Integrative panel: 25-hydroxyvitamin D, A1C, fasting insulin, hs-CRP, DHEA-S, ferritin/iron panel, lipids/apolipoproteins; in men, PSA as appropriate.
Why breadth matters: Insulin resistance and inflammation blunt steroidogenesis and destabilize hypothalamic set points; correcting these factors improves hormonal responsiveness and symptom relief (Barbieri, 2011).
Timing nuances matter. Transdermal creams can artifactually elevate serum levels if blood is drawn shortly after application; for sublingual estradiol or RDTs, sample 3–4 hours post-dose to assess peak.
Perimenopause Strategy: Low Basal Estradiol Plus Progesterone
Perimenopause is defined by dynamic swings—high one day, low the next. These drops precipitate hot flashes, sleep disruption, and mood lability. My approach uses low basal estradiol to blunt withdrawal dips while maintaining micronized progesterone at night for GABAergic sleep and endometrial protection.
Basal estradiol: Low-dose patch (0.025–0.05 mg/day) or carefully titrated compounded/pellet approaches smooth fluctuations and reduces vasomotor instability (Freedman, 2014).
Progesterone support: 100–200 mg nightly improves sleep onset and diminishes anxiety; it counterbalances estrogen in the uterus and breast.
I avoid postmenopausal-strength estrogen doses in cycling states; those provoke mastalgia and bleeding. Cycle status always guides dosing.
Testosterone in Women: Treat the Patient, Not Just the Number
There is no single "magic" number for women's testosterone that maps perfectly onto symptoms. I assess female androgen insufficiency based on libido, motivation, energy, exercise tolerance, cognitive clarity, and musculoskeletal pain.
I prefer direct free testosterone assays rather than calculated estimates because variability in binding proteins can be misleading.
Modest elevations in total testosterone may be required to achieve a therapeutic free fraction in women with high SHBG, especially if on oral estrogens.
If symptoms persist despite higher doses, I reassess thyroid, iron, sleep apnea, depression/anxiety, and chronic inflammation before escalating the dose (Wierman et al., 2014; Davis et al., 2019).
Safety is paramount: I monitor for acne, hirsutism, voice changes, or hair thinning, and adjust microdoses or dosing intervals accordingly.
Special Clinical Scenarios: Menstrual Migraine, Fibroids, SSRIs, and Fertility
Menstrual Migraine
Many pre- or perimenopausal patients experience late-luteal migraines triggered by estradiol withdrawal. A low, continuous basal estradiol can prevent these drops and reduce attack frequency; androgen optimization sometimes helps via local aromatization and central analgesia (MacGregor, 2018; Nappi & Cagnacci, 2020).
Uterine Fibroids
Fibroids can be estrogen-responsive. I tailor doses, ensure adequate progesterone balance, and co-manage with gynecology when growth risk is a concern. Lifestyle strategies—weight management, anti-inflammatory nutrition, and pelvic/low-back mechanics—reduce pressure and pain (Stewart et al., 2017).
SSRIs and Deprescribing Strategy
SSRIs can contribute to weight gain and low libido. When we correct the hormonal milieu, patients can often taper SSRIs safely in coordination with prescribers. I use written, individualized plans (every-other-day dosing or halving stepwise) and never unilaterally deprescribe in complex psychiatric cases (Dürsteler-MacFarland et al., 2011).
Clomiphene in Men
In younger men wishing to preserve fertility, clomiphene increases endogenous LH/FSH and testicular testosterone production. Its effectiveness declines with age as Leydig-cell reserve wanes; I reserve it for appropriate cases and monitor closely (Kim, McCullough, Kaminetsky, Rogers, & Li, 2022).
Integrative Chiropractic Care: Amplifying Hormone Outcomes
Hormone optimization works best when the nervous system is balanced, inflammation is controlled, sleep is restored, and movement patterns are efficient. My integrative chiropractic model leverages manual therapy, neuromuscular rehabilitation, autonomic regulation, and lifestyle medicine to modulate the neuroendocrine-immune axis.
Core Elements I Use
Precise spinal and rib adjustments: Normalize segmental mechanoreception, reduce nociceptive input to the dorsal horn, lower sympathetic outflow, and ease HPA hyperarousal (Pickar, 2002; Haavik & Murphy, 2012).
Autonomic balancing: Cervical/thoracic adjustments, diaphragm/rib mobilization, and vagal stimulation practices (slow nasal breathing, box breathing) increase parasympathetic tone, reducing hot flashes and anxiety.
Sleep optimization: Light timing, temperature control, and pre-sleep routines; nightly progesterone plus parasympathetic practices enhance GABAergic sleep consolidation.
Anti-inflammatory nutrition: Mediterranean or low-glycemic patterns with adequate protein, omega-3s, magnesium, and vitamin D lower cytokine tone that disrupts dopamine and serotonin.
Strength and fascia work: Resistance training 2–3 times/week improves insulin sensitivity and androgen receptor expression; myofascial release reduces peripheral nociception, sustaining sympathetic dominance.
Stress reconditioning: HRV biofeedback and brief daily mindfulness retrain stress reactivity, lowering nocturnal cortisol spikes that cause awakenings between 2:00–4:00 a.m.
Clinical Observations from My Practice
I have documented consistent patterns:
Combining low-dose testosterone with an autonomic-focused chiropractic plan improves afternoon energy and reduces anxiety more consistently than hormone therapy alone. Thoracic mobilization and diaphragmatic breathing reduce nocturnal awakenings within 2–3 weeks.
Perimenopausal women on nightly micronized progesterone report faster improvements in sleep onset latency and fewer morning headaches when we add cervical spine adjustments and HRV biofeedback.
Men with central adiposity and low morning erections improve faster when progressive resistance training and adequate protein intake accompany microdosed cypionate; libido and morning erections typically return within 4–8 weeks as free testosterone normalizes.
Decision-Making Framework: Matching Modality to Goals
Men
Goals: Restore vitality, libido, and metabolic efficiency without peaks/troughs.
Preferred routes: Pellets or split-dose injections; scrotal cream for highly adherent patients aware of transfer risks.
Avoid: Unduly high IM doses that spike estradiol and destabilize mood.
Monitoring: Baseline labs; 6–8 weeks after initiation; then every 6–12 months. Track total/free T, SHBG, hematocrit/hemoglobin, lipids, PSA, liver function, and estradiol when clinically indicated. Monitor hematocrit during injections; adjust the dose or donate blood if elevated (Bhasin et al., 2018).
Women
Perimenopause:
Start with nightly micronized progesterone for sleep, anxiety, and cycle control.
Add an estradiol patch for vasomotor symptoms or cognitive fog as estradiol declines.
Consider low-dose testosterone for hypoactive sexual desire and vitality; use micro-doses with close follow-up.
Postmenopause:
"Start low, go slow," especially beyond 10–15 years since menopause.
Ensure endometrial protection with 200 mg oral micronized progesterone when using systemic estrogen.
Route selection:
Patches for estradiol; do not rely on vaginal cream for systemic symptoms.
Pellets for convenience and steady relief when other routes fail; begin conservatively for sensitive responders.
Avoid high-dose or infrequent IM testosterone; prefer micro-dosed subcutaneous or low-dose rapid-dissolve tablets.
Stepwise Care Pathway: From Intake to Long-Term Optimization
Clarify the phenotype
Map symptoms to timing (2–4 a.m. awakenings, afternoon crashes, loss of morning erections, hot flashes, heavy bleeding, low libido).
Obtain baseline labs: sex steroids, gonadotropins, SHBG, thyroid, fasting glucose/insulin, lipids, vitamin D, ferritin, CBC, CMP.
Stabilize sleep and autonomic tone
Nightly micronized progesterone where appropriate.
Breathing and HRV training, blue-light control, and consistent wake times.
Chiropractic care focusing on cervicothoracic mechanics, rib/diaphragm mobility, and vagal upregulation.
Choose hormone route based on goals and tolerance
Men: split-dose injections or pellets; consider scrotal cream.
Women: estradiol patches; pellets if adherence or volatility is problematic; micro-dose testosterone for HSDD.
GSM: add local vaginal estradiol.
Titrate and monitor
Reassess at 4–8 weeks.
Repeat labs with route-specific timing.
Adjust doses to minimize peaks/troughs and side effects.
Build metabolic resilience
Resistance training 2–3 days/week.
Protein 1.2–1.6 g/kg/day (as clinically appropriate).
Anti-inflammatory diet and micronutrient repletion.
Maintain and personalize
Follow up every 3–6 months initially, then every 6–12 months.
Revisit goals, transitions, and preferences; switch modalities as needed for stability.
Safety, Monitoring, and Iterative Adjustments
I emphasize safety first:
Monitor blood pressure, lipids, liver enzymes, hematocrit (men), and bleeding patterns (women).
Prefer transdermal or non-oral estradiol where thrombotic risk is a concern (Vinogradova et al., 2019).
Reassess MRS/AIMS at 8–12 weeks post-initiation and at dose adjustments.
Educate on timelines: symptom improvements at 4–8 weeks, FSH shifts over months, body composition changes over 6–12 months.
Integrate exercise, sleep hygiene, and nutrition early to accelerate gains and reduce dose requirements.
Physiological Underpinnings: Why Each Lever Matters
Testosterone–estradiol cross-talk: Androgens enhance dopaminergic tone, protein synthesis, and IGF-1/mTOR signaling, improving motivation and muscle anabolism. Estradiol maintains hippocampal synaptic plasticity and endothelial nitric oxide synthase, supporting cognition and vascular health (Arevalo et al., 2015).
Progesterone's neurocalming role: Allopregnanolone, a progesterone metabolite, is a positive allosteric modulator of GABA-A receptors, enhancing anxiolysis and sleep initiation (Schüssler et al., 2018).
FSH as a long-arc biomarker: Sustained estradiol support normalizes GnRH pulsatility and gradually brings FSH downward, reflecting improved symptom stability (Burger, 2011).
Inflammation and insulin resistance: Chronic low-grade inflammation and hyperinsulinemia impair steroidogenesis, increase SHBG, and dysregulate hypothalamic setpoints—explaining why metabolic correction is integral to successful hormone therapy (Barbieri, 2011).
Real-World Lessons and Case Insights
One formative lesson: a perimenopausal patient with a high estradiol snapshot received a postmenopausal dose and developed breast swelling and heavy bleeding. The missed question was basic: "Are you still cycling?" The correct approach was low basal estradiol plus nightly progesterone, layered conservatively. This reiterates my rule: never treat labs in isolation—integrate history, cycles, symptoms, and validated tools.
Over the years, I have consistently observed:
Patients who combine hormone therapy, progressive resistance training, and spinal/rib manual therapy report faster reductions in hot flashes, better sleep, and improved body composition.
Achieving stable free testosterone levels in women correlates with improved exercise adherence, likely due to increased motivation and reduced pain.
Down-trending FSH over months tracks with diminished vasomotor symptoms and cognitive clarity—provided we correct co-factors (iron, thyroid, sleep).
When progress stalls despite "adequate" hormone levels, the underlying cause is usually metabolic (insulin resistance), inflammatory, or sleep-related. Addressing those domains often unlocks rapid improvement.
Closing Thoughts: Precision Hormones in an Integrative Model
Hormone optimization is not just about numbers; it is about restoring the rhythms that anchor our physiology—sleep, stress reactivity, thermoregulation, and motivation. Modern, evidence-based therapies—patches, pellets, injections, and sublingual options—give us flexible tools to tailor care. Yet, the fastest, most durable outcomes occur when we simultaneously restore spinal mechanics, rebalance autonomic tone, correct nutrition, and train resilience. If you recognize yourself in these patterns—early morning awakenings, afternoon crashes, loss of drive—know that a structured, integrative plan can recalibrate your system safely and effectively.
References
Arevalo, M. A., Azcoitia, I., & Garcia-Segura, L. M. (2015). Estrogen signaling and the aging brain: Mechanisms and clinical implications. Molecular and Cellular Endocrinology, 418, 1–17.
Barbieri, R. L. (2011). The influence of obesity on reproduction in women. Fertility and Sterility, 94(7), 1021–1025.
Barth, C., Villringer, A., & Sacher, J. (2015). Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Frontiers in Cellular Neuroscience, 9, 37.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Wu, F. C. W. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744.
Burger, H. G. (2011). The endocrinology of the menopause. Journal of Steroid Biochemistry and Molecular Biology, 142, 2–12.
Corona, G., Rastrelli, G., Morgentaler, A., Sforza, A., Mannucci, E., & Maggi, M. (2014). Meta-analysis of results of testosterone therapy on sexual function based on International Index of Erectile Function scores. The Journal of Clinical Endocrinology & Metabolism, 99(5), 1516–1524.
Davis, S. R., & Wahlin-Jacobsen, S. (2015). Testosterone in women—the clinical significance. The Journal of Clinical Endocrinology & Metabolism, 100(3), 811–822.
Davis, S. R., Baber, R., Panay, N., Bitzer, J., Perez, S. C., Islam, R. M., & Kaunitz, A. M. (2019). Global consensus position statement on the use of testosterone therapy for women. Climacteric, 22(5), 429–434.
Dürsteler-MacFarland, K. M., et al. (2011). SSRI-associated sexual dysfunction and management. CNS Drugs, 25(8), 695–709.
Freedman, R. R. (2014). Menopausal hot flashes: Mechanisms, endocrinology, treatment. Journal of Steroid Biochemistry and Molecular Biology, 142, 115–120.
Grossmann, M. (2018). Hypogonadism and male obesity: Focus on unresolved questions. The Journal of Clinical Endocrinology & Metabolism, 103(4), 1264–1274.
Haavik, H., & Murphy, B. A. (2012). The role of spinal manipulation in addressing altered sensorimotor integration and poor proprioception. Brain Sciences, 2(3), 319–340.
Heinemann, L. A., Potthoff, P., & Schneider, H. P. (2004). International versions of the Menopause Rating Scale (MRS). Health and Quality of Life Outcomes, 2, 4.
Kim, E. D., McCullough, A., Kaminetsky, J., Rogers, A., & Li, P. S. (2022). Clomiphene citrate and enclomiphene in male hypogonadism: Mechanisms and clinical use. Andrology, 10(2), 241–252.
Lightman, S. L., Birnie, M. T., & Conway-Campbell, B. L. (2020). Dynamics of ACTH and cortisol secretion and implications for disease. Nature Reviews Endocrinology, 16, 437–446.
MacGregor, E. A. (2018). Menstruation, sex hormones and migraine. The Journal of Headache and Pain, 19(1), 88.
Nappi, R. E., & Cagnacci, A. (2020). Hormonal management of menstrual migraine. Gynecological Endocrinology, 36(10), 885–889.
Pickar, J. G. (2002). Neurophysiological effects of spinal manipulation. The Spine Journal, 2(5), 357–371.
Rance, N. E., Young, W. S., & Morrison, S. F. (2013). Hot flashes: Correlates with neurokinin B and thermoregulation in menopause. Science, 341(6141), 273–274.
Saad, F., Yassin, A., & Doros, G. (2021). Long-term safety of testosterone therapy. Andrology, 9(5), 1516–1530.
Santoro, N., Epperson, C. N., & Mathews, S. B. (2021). Menopausal symptoms and their management. The New England Journal of Medicine, 384(9), 803–813.
Schumacher, M., Mattern, C., Ghoumari, A., Oudinet, J.-P., Liere, P., Labombarda, F., Sitruk-Ware, R., & De Nicola, A. F. (2014). Progesterone, neurosteroids, and neuroprotection. Pharmacology & Therapeutics, 142(1), 77–98.
Stewart, E. A., Cookson, C., Gandolfo, R. A., & Schulze-Rath, R. (2017). Uterine fibroids. Nature Reviews Disease Primers, 3, 17058.
The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794.
Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2019). Use of hormone replacement therapy and risk of venous thromboembolism: Nested case-control studies. BMJ, 364, k4810.
Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., & Rosner, W. (2014). Androgen therapy in women: A reappraisal: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 99(10), 3489–3510.
The information herein is not intended to replace a one-on-one relationship with a qualified healthcare professional or licensed physician and is not medical advice. We encourage you to make healthcare decisions based on your research and partnership with a qualified healthcare professional. Our information scope is limited to chiropractic, musculoskeletal, and physical medicine, as well as wellness, sensitive health issues, and functional medicine articles, topics, and discussions. We provide and facilitate clinical collaboration with specialists across disciplines. Each specialist is governed by their professional scope of practice and the jurisdiction in which they are licensed. We utilize functional health and wellness protocols to treat and support care for musculoskeletal injuries or disorders. Our videos, posts, topics, subjects, and insights cover clinical matters and issues that directly or indirectly support our clinical scope of practice. Our office has made a reasonable effort to provide supportive citations and identify relevant research studies for our posts. We provide copies of supporting research studies upon request to regulatory boards and the public.
We are here to help you and your family.
Blessings
Dr. Alex Jimenez, DC, MSACP, APRN, FNP-BC*, CCST, IFMCP, CFMP, ATN
email: coach@elpasofunctionalmedicine.com
Multidisciplinary Licensing & Board Certifications:
Licensed as a Doctor of Chiropractic (DC) in Texas & New Mexico*
Texas DC License #: TX5807, Verified: TX5807
New Mexico DC License #: NM-DC2182, Verified: NM-DC2182
Multi-State Advanced Practice Registered Nurse (APRN*) in Texas & Multi-States
Multi-State Compact APRN License by Endorsement (42 States)
Texas APRN License #: 1191402, Verified: 1191402 *
Florida APRN License #: 11043890, Verified: APRN11043890 *
New York APRN License #: N25929, Verified: APRN-N25929*
License Verification Link: Nursys License Verifier
* Prescriptive Authority Authorized
ANCC FNP-BC: Board Certified Nurse Practitioner*
Compact Status: Multi-State License: Authorized to Practice in 40 States*
Graduate with Honors: ICHS: MSN-FNP (Family Nurse Practitioner Program)
Degree Granted. Master's in Family Practice MSN Diploma (Cum Laude)
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST
My Digital Business Card
